In summary, epithalon has been found to: Increase the lifespan of animal test subjects (mice and fruit flies) Restore the circadian rhythm of melatonin and cortisol production in animal test subjects (rhesus monkeys) Prolong the integrity of the eye retina in animal test subjects (rats) Improve visual functions in elderly patients with age-related difficulties Despite these promising results, formal research into epithalon and anti-aging remains lacking, prompting researchers to actively explore the peptide
Two other pharmaceutical companies have their own oral GLP-1 drugs in the works: Orforglipron: Developed by Eli Lilly, its in Phase 3 clinical trials for treating type 2 diabetes and obesity, with an expected September 2025 completion
Seek urgent medical attention for severe abdominal pain or persistent vomiting, as these may indicate serious complications such as pancreatitis
Avoid storing peptides in the freezer unless explicitly recommended by the manufacturer
The peptide reduced motor disability, preserved myelin integrity, and supported neurological function in these experimental paradigms
Adults with excess weight (BMI 30) or BMI 27 with issues like high blood pressure may qualify, along with a commitment to healthy lifestyle changes